Clinical Trial

Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease.

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Allogeneic hematopoietic stem cell transplantation (HTC) is the only curative option for many patients with hematologic malignancies but \>50% of this patients will develop extensive chronic graft-versus-host disease (cGVHD), which remains the most important complication after HTC. Classically, the most effective strategies to prevent GVHD have not improved survival; therefore, the new strategies are being sought. This study is designed in two phases: the main objective for phase I study is the more suitable dose for ixazomib search. Phase II study is designed to evaluate the efficacy of ixazomib at the doses stablished in phase I.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2017-07-18; most recent amendment 2024-08-28.
Status change: Recruiting → Active, Not Recruiting 2023-05-02
Trial Details
NCT Number NCT03225417
Lead Sponsor Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Collaborators: Spanish Clinical Research Network - SCReN
Conditions Hematopoietic Stem Cell Transplantation, Multiple Myeloma
Enrollment 142 participants
Start Date 2017-05-16
Primary Completion 2024-01-11 (estimated)
Study Completion 2024-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-08-30